Literature DB >> 21509801

Prediction model for mortality after intracranial hemorrhage in patients with leukemia.

Farshid Dayyani1, Sarah Schellhorn Mougalian, Kiran Naqvi, Jianqin Shan, Farhad Ravandi, Jorge Cortes, Jeffrey Weinberg, Elias Jabbour, Stefan Faderl, William Wierda, Deborah Thomas, Susan O'Brien, Sherry Pierce, Hagop Kantarjian, Guillermo Garcia-Manero.   

Abstract

Intracranial hemorrhage (ICH) is associated with great morbidity and mortality in patients with acute leukemia. We identified 118 patients with ICH from a total of 2,421 patient with leukemia who were treated at our institution between 2005-2009, and assessed the prognostic factors for mortality in the ICH cohort. Median age at time of ICH was 58 years, 49% were male, and 60% had acute myeloid leukemia. The relative incidence of ICH was highest in patients with chronic myeloid leukemia in blast crisis (12.1%). Mental status changes were the most common symptom which prompted work-up for ICH. Median survival for all patients after onset of ICH was 20 days. In multivariate analyses, four clinical characteristics were identified as independent adverse factors for mortality in patients with ICH: albumin <3.5 g/dL, lactate dehydrogenase (LDH) >835 U/L, age > 60 years, and relapsed disease status. Based on the number of risk factors, mortality after ICH was: 25% (0 risk factor), 47% (1), 78% (2), and >97% (3 or 4). In conclusion, patients with leukemia who develop ICH do not have universally poor outcomes, and a simple scoring system could serve to advise physicians and families of the prognosis and the potential benefit of aggressive treatment options.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21509801      PMCID: PMC4712950          DOI: 10.1002/ajh.22031

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  20 in total

1.  High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia.

Authors:  A H Sarris; S Kempin; E Berman; J Michaeli; C Little; M Andreeff; T Gee; D Straus; B Gansbacher; D Filippa
Journal:  Blood       Date:  1992-03-01       Impact factor: 22.113

Review 2.  Haemostatic problems in acute leukaemia.

Authors:  J T Wilde; J M Davies
Journal:  Blood Rev       Date:  1990-12       Impact factor: 8.250

3.  Disseminated intravascular coagulation in adult acute lymphoblastic leukemia: frequent complications with fibrinogen levels less than 100 mg/dl.

Authors:  A Sarris; J Cortes; H Kantarjian; S Pierce; T Smith; M Keating; C Koller; S Kornblau; S O'Brien; M Andreeff
Journal:  Leuk Lymphoma       Date:  1996-03

4.  Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.

Authors:  Utz Krug; Christoph Röllig; Anja Koschmieder; Achim Heinecke; Maria Cristina Sauerland; Markus Schaich; Christian Thiede; Michael Kramer; Jan Braess; Karsten Spiekermann; Torsten Haferlach; Claudia Haferlach; Steffen Koschmieder; Christian Rohde; Hubert Serve; Bernhard Wörmann; Wolfgang Hiddemann; Gerhard Ehninger; Wolfgang E Berdel; Thomas Büchner; Carsten Müller-Tidow
Journal:  Lancet       Date:  2010-12-03       Impact factor: 79.321

5.  Outcome of patients with acute myelogenous leukemia after second salvage therapy.

Authors:  Francis Giles; Susan O'Brien; Jorge Cortes; Srdan Verstovsek; Carlos Bueso-Ramos; Jianqin Shan; Sherry Pierce; Guillermo Garcia-Manero; Michael Keating; Hagop Kantarjian
Journal:  Cancer       Date:  2005-08-01       Impact factor: 6.860

6.  Acute promyelocytic leukemia: a 5-year experience with new antileukemic agents and a new approach to preventing fatal hemorrhage.

Authors:  E J Feldman; Z A Arlin; T Ahmed; A Mittelman; J L Ascensao; C A Puccio; N Coombe; P Baskind
Journal:  Acta Haematol       Date:  1989       Impact factor: 2.195

7.  Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission.

Authors:  Hagop M Kantarjian; Deborah Thomas; Farhad Ravandi; Stefan Faderl; Guillermo Garcia-Manero; Jianquin Shan; Sherry Pierce; Jorge Cortes; Susan O'Brien
Journal:  Leuk Lymphoma       Date:  2010-01-18

8.  Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia. Associations with hyperleukocytosis and acute monocytic leukemia.

Authors:  U Creutzig; J Ritter; M Budde; A Sutor; G Schellong
Journal:  Cancer       Date:  1987-12-15       Impact factor: 6.860

9.  Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1976-08       Impact factor: 6.998

10.  Causes of death in adults with acute leukemia.

Authors:  H Y Chang; V Rodriguez; G Narboni; G P Bodey; M A Luna; E J Freireich
Journal:  Medicine (Baltimore)       Date:  1976-05       Impact factor: 1.889

View more
  8 in total

Review 1.  How I treat acute myeloid leukemia presenting with preexisting comorbidities.

Authors:  Yishai Ofran; Martin S Tallman; Jacob M Rowe
Journal:  Blood       Date:  2016-05-27       Impact factor: 22.113

2.  Predicting mortality from intracranial hemorrhage in patients who undergo allogeneic hematopoietic stem cell transplantation.

Authors:  Xiying Ren; Qiusha Huang; Qingyuan Qu; Xuan Cai; Haixia Fu; Xiaodong Mo; Yu Wang; Yawei Zheng; Erlie Jiang; Yishan Ye; Yi Luo; Shaozhen Chen; Ting Yang; Yuanyuan Zhang; Wei Han; Feifei Tang; Wenjian Mo; Shunqing Wang; Fei Li; Daihong Liu; Xiaoying Zhang; Yicheng Zhang; Shuqing Feng; Feng Gao; Hailong Yuan; Dao Wang; Dingming Wan; Huan Chen; Yao Chen; Jingzhi Wang; Yuhong Chen; Ying Wang; Kailin Xu; Tao Lang; Xiaomin Wang; Hongbin Meng; Limin Li; Zhiguo Wang; Yanling Fan; Yingjun Chang; Lanping Xu; Xiaojun Huang; Xiaohui Zhang
Journal:  Blood Adv       Date:  2021-12-14

3.  Intracranial hemorrhage in adult patients with hematological malignancies.

Authors:  Chien-Yuan Chen; Chan-Hwei Tai; Aristine Cheng; Hung-Chang Wu; Woei Tsay; Jia-Hau Liu; Pey-Ying Chen; Shang-Yi Huang; Ming Yao; Jih-Luh Tang; Hwei-Fang Tien
Journal:  BMC Med       Date:  2012-08-29       Impact factor: 8.775

4.  Bleeding with negative coagulation screening test as initial presentation of chronic myelogenous leukemia managed by fresh frozen plasma: A case report.

Authors:  Yanzhi Wang; Lina Wang; Yaming Xi; Zijian Li
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

5.  Thrombocytopenia and the effect of platelet transfusions on the occurrence of intracranial hemorrhage in patients with acute leukemia - a nested case-control study.

Authors:  Loes L Cornelissen; Aukje L Kreuger; Camila Caram-Deelder; Rutger A Middelburg; Jean Louis H Kerkhoffs; Peter A von dem Borne; Erik A M Beckers; Karen M K de Vooght; Jürgen Kuball; J J Zwaginga; Johanna G van der Bom
Journal:  Ann Hematol       Date:  2020-10-17       Impact factor: 3.673

6.  Characteristics and Outcomes of Intracranial Hemorrhage in Cancer Patients Visiting the Emergency Department.

Authors:  Aiham Qdaisat; Sai-Ching J Yeung; Cristhiam H Rojas Hernandez; Pavani Samudrala; Mona Kamal; Ziyi Li; Adriana H Wechsler
Journal:  J Clin Med       Date:  2022-01-27       Impact factor: 4.241

7.  Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy.

Authors:  Jurjen Versluis; Manu Pandey; Yael Flamand; J Erika Haydu; Roger Belizaire; Mark Faber; Rahul S Vedula; Anne Charles; Kevin M Copson; Shai Shimony; Alon Rozental; Pavan K Bendapudi; Ofir Wolach; Elizabeth A Griffiths; James E Thompson; Richard M Stone; Daniel J DeAngelo; Donna Neuberg; Marlise R Luskin; Eunice S Wang; R Coleman Lindsley
Journal:  Blood Adv       Date:  2022-05-10

8.  Intracerebral Hemorrhage as the Initial Presentation of Chronic Myeloid Leukemia: A Case Report and Review of the Literature.

Authors:  Huafeng Wang; Fei Cao; Jianhu Li; Ke Sun; Jie Jin; Ming Wang
Journal:  Front Neurol       Date:  2020-10-22       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.